SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    I. Carey, M. Bruce, M. Horner, Y. Zen, L. D'Antiga, S. Bansal, D. Vergani, G. Mieli-Vergani, HBsAg plasma level kinetics: a new role for an old marker as a therapy response predictor in vertically infected children on combination therapy, Journal of Viral Hepatitis, 2014, 21, 12
  2. You have free access to this content2
    Michelle Martinot-Peignoux, Martine Lapalus, Tarik Asselah, Patrick Marcellin, HBsAg quantification: useful for monitoring natural history and treatment outcome, Liver International, 2014, 34,
  3. 3
    Margo J. H. van Campenhout, Harry L. A. Janssen, How to achieve immune control in chronic hepatitis B?, Hepatology International, 2014,

    CrossRef

  4. 4
    Monica A. Konerman, Anna S. Lok, Is It More Cost-effective for Patients With Chronic Hepatitis B to Have a Trial of Interferon Before Considering Nucleos(t)ide Analogue Therapy?, Clinical Gastroenterology and Hepatology, 2014,

    CrossRef

  5. 5
    Tai-Chung Tseng, Jia-Horng Kao, Ding-Shinn Chen, Peginterferon α in the treatment of chronic hepatitis B, Expert Opinion on Biological Therapy, 2014, 14, 7, 995

    CrossRef

  6. 6
    Phunchai Charatcharoenwitthaya, Teerha Piratvisuth, Baseline and On-treatment Predictors of Chronic Hepatitis B Patients Receiving Pegylated Interferon Therapy in Asia, Current Hepatitis Reports, 2013, 12, 3, 165

    CrossRef

  7. 7
    Michelle Martinot-Peignoux, Tarik Asselah, Patrick Marcellin, HBsAg Quantification to Predict Natural History and Treatment Outcome in Chronic Hepatitis B Patients, Clinics in Liver Disease, 2013, 17, 3, 399

    CrossRef

  8. 8
    Teerha Piratvisuth, Patrick Marcellin, Matei Popescu, Hans-Peter Kapprell, Vivien Rothe, Zhi-Meng Lu, Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients, Hepatology International, 2013, 7, 2, 429

    CrossRef

  9. 9
    Elisabetta Degasperi, Mauro Viganò, Alessio Aghemo, Pietro Lampertico, Massimo Colombo, PegIFN-α2a for the treatment of chronic hepatitis B and C: a 10-year history, Expert Review of Anti-infective Therapy, 2013, 11, 5, 459

    CrossRef

  10. 10
    P. Arends, H. L. A. Janssen, Response Guided Treatment for Peginterferon in Chronic Hepatitis B, Current Hepatitis Reports, 2013, 12, 2, 88

    CrossRef

  11. 11
    Milan J. Sonneveld, Bettina E. Hansen, Teerha Piratvisuth, Ji-Dong Jia, Stefan Zeuzem, Edward Gane, Yun-Fan Liaw, Qing Xie, E. Jenny Heathcote, Henry L.-Y. Chan, Harry L.A. Janssen, Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels, Hepatology, 2013, 58, 3
  12. 12
    Mauro Viganò, Giampaolo Mangia, Pietro Lampertico, Results of Treatment of Chronic Hepatitis B with Pegylated Interferon, Clinics in Liver Disease, 2013, 17, 3, 425

    CrossRef

  13. You have free access to this content13
    Michelle Martinot-Peignoux, Martine Lapalus, Tarik Asselah, Patrick Marcellin, The role of HBsAg quantification for monitoring natural history and treatment outcome, Liver International, 2013, 33,
  14. 14
    Yun-Fan Liaw, Jia-Horng Kao, Teerha Piratvisuth, Henry Lik Yuen Chan, Rong-Nan Chien, Chun-Jen Liu, Ed Gane, Stephen Locarnini, Seng-Gee Lim, Kwang-Hyub Han, Deepak Amarapurkar, Graham Cooksley, Wasim Jafri, Rosmawati Mohamed, Jin-Lin Hou, Wan-Long Chuang, Laurentius A. Lesmana, Jose D. Sollano, Dong-Jin Suh, Masao Omata, Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update, Hepatology International, 2012, 6, 3, 531

    CrossRef

  15. 15
    Sarah Maylin, Quantification de l’AgHBs : nouvel outil virologique pour la prise en charge de l’hépatite B chronique, Revue Francophone des Laboratoires, 2012, 2012, 447, 33

    CrossRef

  16. 16
    Yun-Fan Liaw, Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: A review, Hepatology, 2011, 53, 6
  17. 17
    Yun-Fan Liaw, Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: A review, Hepatology, 2011, 54, 2
  18. 18
    Henry Lik-Yuen Chan, Alex Thompson, Michelle Martinot-Peignoux, Teerha Piratvisuth, Markus Cornberg, Maurizia Rossana Brunetto, Hans L. Tillmann, Jia-Horng Kao, Ji-Dong Jia, Heiner Wedemeyer, Stephen Locarnini, Harry L.A. Janssen, Patrick Marcellin, Hepatitis B surface antigen quantification: Why and how to use it in 2011 – A core group report, Journal of Hepatology, 2011, 55, 5, 1121

    CrossRef

  19. 19
    Beom Kyung Kim, Kwang-Hyub Han, Sang Hoon Ahn, Hepatitis B Virus Serology to Predict Antiviral Response in Chronic Hepatitis B, Digestion, 2011, 84, s1, 29

    CrossRef

  20. 20
    Y.-F. Liaw, J.-D. Jia, H.L.Y. Chan, K.H. Han, T. Tanwandee, W.L. Chuang, D.M. Tan, X.Y. Chen, E. Gane, T. Piratvisuth, L. Chen, Q. Xie, J.J.Y. Sung, C. Wat, C. Bernaards, Y. Cui, P. Marcellin, Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C, Hepatology, 2011, 54, 5